MedPath

Fosinopril

Generic Name
Fosinopril
Drug Type
Small Molecule
Chemical Formula
C30H46NO7P
CAS Number
98048-97-6
Unique Ingredient Identifier
R43D2573WO
Background

Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Indication

For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Associated Conditions
Heart Failure, Hypertension

Prevention of Renal and Vascular Endstage Disease Intervention Trial

Phase 3
Completed
Conditions
Microalbuminuria
Renal Disease
Cardiovascular Diseases
Interventions
First Posted Date
2017-03-08
Last Posted Date
2017-03-10
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
864
Registration Number
NCT03073018

Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension

Phase 4
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2016-01-05
Last Posted Date
2016-01-05
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
508
Registration Number
NCT02646397
Locations
🇨🇳

Department of Nephrology, Shanghai Changzheng Hospital, Shanghai, Shanghai, China

The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension

Not Applicable
Completed
Conditions
Diabetes Mellitus
Essential Hypertension
Interventions
First Posted Date
2011-04-27
Last Posted Date
2011-05-13
Lead Sponsor
China-Japan Friendship Hospital
Target Recruit Count
140
Registration Number
NCT01342614

Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)

Phase 4
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Other: lactose
First Posted Date
2009-11-17
Last Posted Date
2015-03-25
Lead Sponsor
Imperial College London
Target Recruit Count
80
Registration Number
NCT01014338
Locations
🇬🇧

Royal Brompton Hospital, London, United Kingdom

Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions

Not Applicable
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-10-23
Last Posted Date
2008-10-23
Lead Sponsor
Ranbaxy Laboratories Limited
Target Recruit Count
34
Registration Number
NCT00777972
Locations
🇺🇸

Gateway Medical Research Inc, St Charles, Missouri, United States

Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions

Not Applicable
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-10-23
Last Posted Date
2008-10-23
Lead Sponsor
Ranbaxy Laboratories Limited
Target Recruit Count
33
Registration Number
NCT00778713
Locations
🇺🇸

Gateway Medical Research Inc, St. Charles, Missouri, United States

Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions

Not Applicable
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-10-21
Last Posted Date
2008-10-21
Lead Sponsor
Ranbaxy Laboratories Limited
Target Recruit Count
24
Registration Number
NCT00776672
Locations
🇺🇸

Gateway Medical Research Inc., St.charles, Missouri, United States

Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions

Not Applicable
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-10-21
Last Posted Date
2008-10-21
Lead Sponsor
Ranbaxy Laboratories Limited
Target Recruit Count
40
Registration Number
NCT00776334
Locations
🇺🇸

Gateway Medical Research Inc., St.charles, Missouri, United States

Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3

Not Applicable
Conditions
Chronic Kidney Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II Type 1 Receptor Blockers
Proteinuria
Interventions
First Posted Date
2007-11-30
Last Posted Date
2007-11-30
Lead Sponsor
Shanghai Municipal Health Bureau
Target Recruit Count
400
Registration Number
NCT00565396
Locations
🇨🇳

Xiangshan People's Hospital, Xiangshan, Zhejiang, China

🇨🇳

Renji Hospital, Shanghai, China

🇨🇳

Shanghai 6th people's hospital, Shanghai, China

and more 23 locations

Eplerenone, ACE Inhibition and Albuminuria

Phase 2
Completed
Conditions
Diabetic Nephropathy
Interventions
First Posted Date
2006-04-17
Last Posted Date
2012-05-28
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
30
Registration Number
NCT00315016
Locations
🇳🇱

Jeroen Bosch Hospital, 's-Hertogenbosch, Noord Brabant, Netherlands

🇳🇱

University Medical Center Nijmegen St Radboud, Nijmegen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath